Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil

Braz J Otorhinolaryngol. 2022 May-Jun;88(3):471-480. doi: 10.1016/j.bjorl.2021.03.003. Epub 2021 Apr 3.

Abstract

Introduction: Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual's quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment.

Objective: To review the current status of biologic treatment indications in chronic rhinosinusitis.

Methods: The Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality.

Results: Of particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio.

Conclusion: The use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience.

Keywords: Chronic rhinosinusitis; Immunobiologicals; Monoclonal antibody; Nasal polyps.

Publication types

  • Review

MeSH terms

  • Biological Products* / therapeutic use
  • Brazil
  • Chronic Disease
  • Humans
  • Nasal Polyps* / complications
  • Nasal Polyps* / drug therapy
  • Quality of Life
  • Rhinitis* / complications
  • Rhinitis* / drug therapy
  • Sinusitis* / complications
  • Sinusitis* / drug therapy

Substances

  • Biological Products